Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes

Kimura, Tomohiko; Kaneto, Hideaki; Shimoda, Masashi; Hirukawa, Hidenori; Okauchi, Seizo; Kohara, Kenji; Hamamoto, Sumiko; Tawaramoto, Kazuhito; Hashiramoto, Mitsuru; Kaku, Kohei

doi:10.1016/j.mce.2014.11.018

Cited by 53 publications

(52 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…113 In animal studies, the protective effects of liraglutide on betacell function were more pronounced in the early stages of T2D than in the advanced stages. 114 This reflects clinical studies in which the effect size of GLP-1 agonists on glycaemic control correlates with duration of T2D. 115 Uncertainty remains regarding the optimal duration of treatment and durability of effect.…”

Section: Sglt-2 Inhibitorsmentioning

confidence: 99%

Targeting beta-cell preservation in the management of type 2 diabetes

2017

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is widely considered a chronic and progressive disease without cure. As beta-cell function progressively declines over time, blood glucose rises. Current management of T2D involves incremental introduction of dietary and drug therapies to achieve normoglycaemia. However, recent studies have demonstrated remission of T2D following bariatric surgery, very low calorie diet or intensive insulin therapy, raising the possibility that the declining beta-cell function in T2D may be arrested or even reversed. The point at which such interventions are introduced in the course of T2D is key for clinical benefit. Future treatment strategies should be revised to target early betacell preservation and thus disease remission. This article reviews the pathogenesis of beta-cell dysfunction and evidence for the clinical benefit of preserving beta-cell function in T2D, and discusses the evidence for beta-cell preservation of current glucose-lowering therapies with particular reference to their effect when initiated at the time of diagnosis of T2D. Br J Diabetes 2017;17:134-144

show abstract

Section: Sglt-2 Inhibitorsmentioning

confidence: 99%

Targeting beta-cell preservation in the management of type 2 diabetes

2017

View full text Add to dashboard Cite

show abstract

“…Inhibitors of SGLT2 directly target the kidneys, without requiring insulin secretion or action, to decrease plasma glucose concentrations and are currently being used as an insulin‐independent treatment for diabetes. However, it has been reported that β‐cell dysfunction is mitigated by appropriate intervention with some antidiabetic agents . At this point, SGLT2 inhibitors are superior to other antidiabetic drugs.…”

Section: Glucose Toxicity In the Development Of Insulin Resistance Anmentioning

confidence: 99%

“…However, it has been reported that β-cell dysfunction is mitigated by appropriate intervention with some antidiabetic agents. [26][27][28][29][30][31][32] At this point, SGLT2 inhibitors are superior to other antidiabetic drugs.…”

Section: Introductionmentioning

confidence: 99%

Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β‐cell function and reduction of insulin resistance

Kaneto

Obata

Kimura

et al. 2016

Journal of Diabetes

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes mellitus is characterized by insulin resistance in various insulin target tissues, such as the liver, adipose tissue, and skeletal muscle, and insufficient insulin secretion from pancreatic β-cells. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are newly developed antidiabetic agents, decrease blood glucose levels by enhancing urinary glucose excretion and thereby function in an insulin-independent manner. Sodium-glucose cotransporter 2 inhibitors exert beneficial effects to reduce insulin resistance and preserve pancreatic β-cell function. In addition, SGLT2 inhibitors exhibit a variety of beneficial effects in various insulin target tissues, such as amelioration of fatty liver, reduction of visceral fat mass, and increasing glucose uptake in skeletal muscle. Furthermore, SGLT2 inhibitors protect pancreatic β-cells against glucose toxicity and preserve insulin secretory capacity. Together, these observations indicate that SGLT2 inhibitors are promising newly developed antidiabetic agents that are gaining attention in both clinical medicine and basic research.

show abstract

“…In many reports, however, intervention took place at a relatively early stage of diabetes . Recently, we reported that pharmacological intervention such as treatment with thiazolidine and a GLP‐1 receptor agonist was more effective at an early rather than advanced stage of diabetes …”

Section: Introductionmentioning

confidence: 99%